The signal pathways and treatment of cytokine storm in COVID-19

L Yang, X Xie, Z Tu, J Fu, D Xu, Y Zhou - Signal transduction and …, 2021 - nature.com
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …

Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

A Bonaventura, A Vecchié, L Dagna… - Nature Reviews …, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe …

Cytokine storm in COVID-19: immunopathogenesis and therapy

C Zanza, T Romenskaya, AC Manetti, F Franceschi… - Medicina, 2022 - mdpi.com
A cytokine storm is a hyperinflammatory state secondary to the excessive production of
cytokines by a deregulated immune system. It manifests clinically as an influenza-like …

Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19

AK Azkur, M Akdis, D Azkur, M Sokolowska… - Allergy, 2020 - Wiley Online Library
As a zoonotic disease that has already spread globally to several million human beings and
possibly to domestic and wild animals, eradication of coronavirus disease 2019 (COVID‐19) …

The pathogenesis and treatment of theCytokine Storm'in COVID-19

Q Ye, B Wang, J Mao - Journal of infection, 2020 - Elsevier
Cytokine storm is a general term applied to maladaptive cytokine release in response to
infection and other stimuli. The pathogenesis is complex but includes loss of regulatory …

The 'cytokine storm': molecular mechanisms and therapeutic prospects

R Karki, TD Kanneganti - Trends in immunology, 2021 - cell.com
Cytokine storm syndrome (CSS) has generally been described as a collection of clinical
manifestations resulting from an overactivated immune system. Cytokine storms (CSs) are …

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

C Zhang, Z Wu, JW Li, H Zhao, GQ Wang - International journal of …, 2020 - Elsevier
Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19),
from Wuhan, China, has swept the world. Although the case fatality rate is not high, the …

[HTML][HTML] Targeting potential drivers of COVID-19: Neutrophil extracellular traps

BJ Barnes, JM Adrover, A Baxter-Stoltzfus… - Journal of Experimental …, 2020 - rupress.org
Disclosures: MR Looney reported" other" from Neutrolis outside the submitted work. RE
Schwartz is a Sponsored Advisory Board Member for Miromatrix Inc. JD Spicer reported …

Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic …

PC Evans, GE Rainger, JC Mason… - Cardiovascular …, 2020 - academic.oup.com
The COVID-19 pandemic is an unprecedented healthcare emergency causing mortality and
illness across the world. Although primarily affecting the lungs, the SARS-CoV-2 virus also …

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from …

W Zhang, Y Zhao, F Zhang, Q Wang, T Li, Z Liu… - Clinical …, 2020 - Elsevier
The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all
over the world. Reports from China showed that about 20% of patients developed severe …